ANIP
$31.33
ANI Pharma
$.27
.87%
ANIP
Earnings Whisper ®
N/A
2nd Quarter June 2020
Consensus:  $0.86
Revenue:  $51.70 Mil
Thursday
Aug 6
8:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ANIP reports earnings?
Beat
Meet
Miss

Where is ANIP's stock price going from here?
Up
Flat
Down
Stock chart of ANIP
Analysts
Summary of analysts' recommendations for ANIP
Score
Grade
Pivots
Resistance
$32.71
$31.95
$31.51

$30.75

Support
$30.31
$29.55
$29.11
Tweet
Growth
Description
ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN.
Peers
BiogenAmgenGilead SciencesNeurocrine BiosciencesBluebird BioSeattle GeneticsQiagen N.V.RepligenBio-TechneNovavax